Danaher (DHR) to Release Quarterly Earnings on Tuesday

Danaher (NYSE:DHR) will be posting its quarterly earnings results before the market opens on Tuesday, April 23rd. Analysts expect Danaher to post earnings of $1.74 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating the consensus estimate of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.87 EPS. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Stock Down 0.1 %

DHR stock opened at $239.66 on Tuesday. The firm’s fifty day simple moving average is $249.58 and its 200-day simple moving average is $229.84. Danaher has a 12 month low of $182.09 and a 12 month high of $259.00. The company has a market capitalization of $177.48 billion, a P/E ratio of 37.51, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a dividend of $0.27 per share. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio is 16.90%.

Insider Activity at Danaher

In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,957 shares of company stock worth $8,265,802. Corporate insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hobbs Group Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter worth approximately $43,000. Sanibel Captiva Trust Company Inc. purchased a new stake in shares of Danaher during the 4th quarter worth approximately $4,194,000. Oarsman Capital Inc. raised its position in Danaher by 54.0% in the 4th quarter. Oarsman Capital Inc. now owns 1,466 shares of the conglomerate’s stock valued at $339,000 after purchasing an additional 514 shares during the last quarter. Harbour Investments Inc. raised its position in Danaher by 14.8% in the 4th quarter. Harbour Investments Inc. now owns 1,429 shares of the conglomerate’s stock valued at $331,000 after purchasing an additional 184 shares during the last quarter. Finally, O Dell Group LLC purchased a new stake in Danaher in the 4th quarter valued at $64,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on DHR shares. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. KeyCorp upped their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. upped their price objective on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. Raymond James upped their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Barclays upped their price objective on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.43.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.